June 20, 2023
- June 20, 2023 - Notice of Change to Funding Opportunity: RADx- UP Dissemination and Implementation (D&I) Research on COVID-19 Testing Interventions among Underserved and Vulnerable Populations (R01 Clinical Trial Optional). See Notice NOT-OD-23-138.
- May 17, 2023 - Notice of NEI Participation in RFA-OD-23-051, "Emergency Award: RADx-UP Dissemination and Implementation (D&I) Research on COVID-19 Testing Interventions among Underserved and Vulnerable Populations (R01 Clinical Trial Optional)". See Notice NOT-EY-23-007
- May 2, 2023 - Emergency Award: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed). See Notice RFA-OD-23-050.
- May 2, 2023 - Emergency Award: RADx- UP Dissemination and Implementation (D&I) Research on COVID-19 Testing Interventions among Underserved and Vulnerable Populations (R01 Clinical Trial Optional). See Notice RFA-OD-23-051
- August 31, 2022 - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
- August 5, 2022 - Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
National Institute on Drug Abuse (NIDA)
This notice corrects RFA-OD-23-050 Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed) to remove the emergency designation and extend the review and award cycle dates.
Changes to the notice of funding opportunity (NOFO) are shown below:
Currently reads:
Title of funding opportunity:
Emergency Award: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed)
Current key dates:
Application due dates: July 3, 2023
Review and award cycles:
Scientific Review Merit: August 2023
Advisory Council Review: Not Applicable
Earliest Start Date: September 2023
Expiration date: July 4, 2023
Section II. Award Information
Funds Available and Anticipated Number of Awards: The number of awards is contingent upon availability of funding and the submission of a sufficient number of meritorious applications. NIH estimates a commitment of $2,800,000M in FY 2023 for ~4-7 awards. Awards may be multi-year funded.
Award Budget: Application budgets are limited to a total of $275,000 direct costs over the two-year project period.
Award Project Period: The maximum project period is two years.
Section IV. Application and Submission Information
6. Funding Restrictions: All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Awards issued under this NOFO may be incrementally funded awards for each budget period with a project period of 2 years. NIH will not issue any awards under this NOFO for a single budget period for multiple years.
Modified to Read (changes shown in bold italics):
Title of funding opportunity: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed)
Key dates:
Application due dates: July 3, 2023
Review and award cycles:
Scientific Review Merit: October 2023
Advisory Council Review: January 2024
Earliest Start Date: March 2024
Expiration date: July 4, 2023
Section II. Award Information
Funds Available and Anticipated Number of Awards: The number of awards is contingent upon availability of funding and the submission of a sufficient number of meritorious applications. NIH estimates a commitment of the following amounts in FY 2024: $1,500,000, 4-7 awards.
Award Budget: Application budgets are limited to a total of $275,000 direct costs over the two-year project period.
Award Project Period: The maximum project period is two years.
Section IV. Application and Submission Information
6. Funding Restrictions:
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Karen Nieves Lugo, PhD, MPH
National Institute on Minority Health and Health Disparities
[email protected]
301-480-4727
and Human Services (HHS)
